160 related articles for article (PubMed ID: 22793259)
1. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
Shen Y; Ruan M; Luo Q; Yu Y; Lu H; Zhu R; Chen L
Thyroid; 2012 Aug; 22(8):856-60. PubMed ID: 22793259
[TBL] [Abstract][Full Text] [Related]
2. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Chen L; Shen Y; Luo Q; Yu Y; Lu H; Zhu R
Thyroid; 2011 Feb; 21(2):119-24. PubMed ID: 21186953
[TBL] [Abstract][Full Text] [Related]
3. Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma.
Liu M; Shen Y; Ruan M; Li M; Chen L
Thyroid; 2014 Jul; 24(7):1179-83. PubMed ID: 24684401
[TBL] [Abstract][Full Text] [Related]
4. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
5. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Hoftijzer H; Heemstra KA; Morreau H; Stokkel MP; Corssmit EP; Gelderblom H; Weijers K; Pereira AM; Huijberts M; Kapiteijn E; Romijn JA; Smit JW
Eur J Endocrinol; 2009 Dec; 161(6):923-31. PubMed ID: 19773371
[TBL] [Abstract][Full Text] [Related]
7. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Waguespack SG; Sherman SI; Williams MD; Clayman GL; Herzog CE
Thyroid; 2009 Apr; 19(4):407-12. PubMed ID: 19355831
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
9. Treatment with sorafenib in advanced thyroid cancer - a case report.
Krajewska J; Olczyk T; Roskosz J; Paliczk-Cieślik E; Smietana AK; Kaczmarek-Borowska B; Jarząb B
Endokrynol Pol; 2010; 61(5):492-6. PubMed ID: 21049464
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
11. Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Eisner F; Schaberl-Moser R; Gerger A; Samonigg H; Pichler M
Onkologie; 2013; 36(6):368-70. PubMed ID: 23774152
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
13. Thyroid follicular carcinoma metastasized to the lung, skull, and brain 12 years after initial treatment for thyroid gland--case report.
Ogawa Y; Sugawara T; Seki H; Sakuma T
Neurol Med Chir (Tokyo); 2006 Jun; 46(6):302-5. PubMed ID: 16794352
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
15. Response to sorafenib treatment in advanced metastatic thyroid cancer.
Pitoia F
Arq Bras Endocrinol Metabol; 2014 Feb; 58(1):37-41. PubMed ID: 24728162
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Ahmed M; Barbachano Y; Riddell A; Hickey J; Newbold KL; Viros A; Harrington KJ; Marais R; Nutting CM
Eur J Endocrinol; 2011 Aug; 165(2):315-22. PubMed ID: 21566072
[TBL] [Abstract][Full Text] [Related]
17. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Fagin JA; Tuttle RM; Pfister DG
J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
[No Abstract] [Full Text] [Related]
18. Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
Gudena V; Verma N; Post G; Kizziah M; Fenning R; Montero AJ
Cancer Biol Ther; 2008 Jun; 7(6):810-3. PubMed ID: 18376142
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of sorafenib in advanced thyroid cancer.
Gupta-Abramson V; Troxel AB; Nellore A; Puttaswamy K; Redlinger M; Ransone K; Mandel SJ; Flaherty KT; Loevner LA; O'Dwyer PJ; Brose MS
J Clin Oncol; 2008 Oct; 26(29):4714-9. PubMed ID: 18541894
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
